Translation of "Common adverse events" in German

The most common adverse events reported were local reactions at the injection site.

The most common adverse events are displayed in table 1 below.

The most common treatment-emergent adverse events were hand-foot skin reaction, diarrhea, fatigue and hypertension.

Under these circumstances, less common adverse events may be detected.

The most common adverse events were somnolence, decreased appetite, and diarrhoea.

The most common adverse events were rash, photosensitivity, hair loss, and joint pain.

The most common adverse events seen were dry mouth, constipation, headache, dyspepsia and nasal dryness.

The most common adverse events in children and adolescents 6 to 17 years of age were:

Most common adverse events were: dizziness (9.7%) and dry mouth (7.1%).

A preliminary safety assessment showed the most common adverse events were consistent with previous experience with vismodegib.

The most common adverse events were pain, swelling, numbness, bruising and induration.

The most common adverse events were rash, photosensitivity, joint pain, hair loss and fatigue.

The most common, non-serious, adverse events reported are upper respiratory tract infection, nasopharyngitis, headache and hypertension.

All other common adverse events resolved in the majority of patients.

The most common adverse events observed in the 12-week study with pregabalin treatment were somnolence, pyrexia, upper respiratory tract infection, increased appetite, weight increased, and nasopharyngitis (see sections 4.2, 5.1 and 5.2).

Hypertension and type 2 diabetes with renal disease In a controlled clinical trial in type 2 diabetic patients with proteinuria (RENAAL study, see section 5.1) the most common drug-related adverse events which were reported for losartan are as follows: Nervous system disorders: common: dizziness

In these two studies, clinically important and most common adverse events included dizziness, headache and dyslipidemia.

The most common adverse events reported from the clinical studies are headache, dizziness and gastro-intestinal events like diarrhoea, nausea, abdominal pain and rectal bleeding.

The most common treatment-emergent adverse events among patients receiving 30 mg were extrapyramidal disorder (28.3%), somnolence (27.3%), headache (23.2%), and nausea (14.1%).

The most common adverse events (? 10%) in subjects taking varenicline were nausea (27.0% vs. 10.4% on placebo), headache (16.8% vs. 11.2%), abnormal dreams (11.3% vs. 8.2%), insomnia (10.9% vs. 4.8%) and irritability (10.9% vs. 8.2%).

The most common adverse events in subjects taking varenicline were nausea (23.8% vs. 14.0% on placebo), headache (10.7% vs. 18.6% on placebo) and vomiting (10.7% vs. 9.3% on placebo).

The most common adverse events leading to withdrawal in either treatment group were nausea and vomiting.

A detailed assessment of the most common adverse events in the target population (IRLS baseline score 24-40 points) has been provided.

Common adverse events which led to treatment discontinuation of bortezomib and Caelyx included PPE, neuralgia, peripheral neuropathy, peripheral sensory neuropathy, thrombocytopaenia, decreased ejection fraction, and fatigue.

The most common adverse events were transient local reactions (pain, redness, swelling at the injection site) and systemic reactions (loss of appetite, fever, drowsiness, irritability).

Other less common adverse events (between 1 and 10 patients out of 100 treated) reported in association with interferon beta include diarrhoea, loss of appetite, vomiting, sleeping difficulty, dizziness, nervousness, itching, rash, nettle-rash, hair loss, dilatation of the blood vessels and palpitation, irregularities and/or changes in menstrual flow and serious reactions of the skin and mucous membranes.

The most common adverse events with at least a possible relation to telbivudine were grade 3/ 4 blood creatine kinase elevations (6.8%), fatigue (4.4%), headache (3.0%) and nausea (2.6%).